This approval helps address an urgent unmet need, with about half of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy
Pfizer to discuss regulatory submission with FDA, potentially leading to eighth indication for ADCETRIS
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement
Comprehensive clinical development programs being initiated for each investigational candidate
The company has received five final approvals
Cyclophosphamide is a chemotherapy medication that slows the growth of cancer cell
The product will be manufactured at Lupin's Pithampur facility in India
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
Expanding to states like Maharashtra, Andhra Pradesh, Telangana, and Manipur while marking the significant milestone in its journey towards providing accessible healthcare services
Subscribe To Our Newsletter & Stay Updated
